216 related articles for article (PubMed ID: 34998918)
21. Human T cell glycosylation and implications on immune therapy for cancer.
De Bousser E; Meuris L; Callewaert N; Festjens N
Hum Vaccin Immunother; 2020 Oct; 16(10):2374-2388. PubMed ID: 32186959
[TBL] [Abstract][Full Text] [Related]
22. Revitalizing Cytokine-Based Cancer Immunotherapy through Advanced Delivery Systems.
Chen P; Paraiso WKD; Cabral H
Macromol Biosci; 2023 Dec; 23(12):e2300275. PubMed ID: 37565723
[TBL] [Abstract][Full Text] [Related]
23. Protein-glycan interactions in the control of innate and adaptive immune responses.
van Kooyk Y; Rabinovich GA
Nat Immunol; 2008 Jun; 9(6):593-601. PubMed ID: 18490910
[TBL] [Abstract][Full Text] [Related]
24. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
25. Nanotechnology platforms for cancer immunotherapy.
Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
[TBL] [Abstract][Full Text] [Related]
26. Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms.
Davicino RC; Eliçabe RJ; Di Genaro MS; Rabinovich GA
Int Immunopharmacol; 2011 Oct; 11(10):1457-63. PubMed ID: 21600310
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
Li L; Yang Z; Chen X
Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
Liu J; Zhang R; Xu ZP
Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
[TBL] [Abstract][Full Text] [Related]
29. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review.
Maverakis E; Kim K; Shimoda M; Gershwin ME; Patel F; Wilken R; Raychaudhuri S; Ruhaak LR; Lebrilla CB
J Autoimmun; 2015 Feb; 57():1-13. PubMed ID: 25578468
[TBL] [Abstract][Full Text] [Related]
30. Glycan gimmickry by parasitic helminths: a strategy for modulating the host immune response?
van Die I; Cummings RD
Glycobiology; 2010 Jan; 20(1):2-12. PubMed ID: 19748975
[TBL] [Abstract][Full Text] [Related]
31. Glycans as shapers of tumour microenvironment: A sweet driver of T-cell-mediated anti-tumour immune response.
Fernandes Â; Azevedo CM; Silva MC; Faria G; Dantas CS; Vicente MM; Pinho SS
Immunology; 2023 Feb; 168(2):217-232. PubMed ID: 35574724
[TBL] [Abstract][Full Text] [Related]
32. Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.
Chiang AWT; Baghdassarian HM; Kellman BP; Bao B; Sorrentino JT; Liang C; Kuo CC; Masson HO; Lewis NE
J Biomed Sci; 2021 Jun; 28(1):50. PubMed ID: 34158025
[TBL] [Abstract][Full Text] [Related]
33. Engineering nanoparticle strategies for effective cancer immunotherapy.
Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
[TBL] [Abstract][Full Text] [Related]
34. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
35. [Development of a Nano DDS for Cancer Immunotherapy Based on Llipid Nanoparticles].
Nakamura T
Yakugaku Zasshi; 2018; 138(12):1443-1449. PubMed ID: 30504656
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
Chyuan IT; Chu CL; Hsu PN
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
38. The role of glycosylation in clinical allergy and immunology.
Hale RC; Morais D; Chou J; Stowell SR
J Allergy Clin Immunol; 2024 Jan; 153(1):55-66. PubMed ID: 37717626
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
40. Metallic Nanoparticles for Cancer Immunotherapy.
Evans ER; Bugga P; Asthana V; Drezek R
Mater Today (Kidlington); 2018; 21(6):673-685. PubMed ID: 30197553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
